These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24238261)

  • 1. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
    Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
    Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
    J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations.
    Vadcharavivad S; Praisuwan S; Techawathanawanna N; Treyaprasert W; Avihingsanon Y
    J Clin Pharm Ther; 2016 Jun; 41(3):310-28. PubMed ID: 27191538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
    Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
    Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
    Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
    Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
    Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
    Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
    Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
    J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.